Leukemia Treatment Articles & Analysis
29 news found
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting. ...
“These data suggest that treatment with a one-time allogeneic gamma-delta T cell therapy has the potential to disrupt the treatment paradigm for AML. ...
Those include IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for the treatment of acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), and ...
I look forward to working with this talented and passionate management team to accelerate the development of Immune-Onc's portfolio of products that may improve outcomes for cancer patients who currently have limited treatment options,” said Mr. Whitmore. Mr. Whitmore is a highly accomplished financial executive who has more than 20 years of experience in strategic ...
“Based on strong preclinical and emerging clinical data, we believe there is good synergy between PD-1 and LILRB antagonists for the treatment of solid tumors. We look forward to working with Immune-Onc to explore the possibility of combination therapy with our products, which may bring more treatment options to cancer patients in ...
“I am so honored and pleased to see our vision of cancer research come closer to trial and real-time treatment of patients. This has been my lifelong dream and is the most fulfilling way to honor my son, Evan Dunbar, my wife, Dr. ...
The multicenter Phase 1 trial in China will evaluate the safety, tolerability, pharmacokinetics, and efficacy of IO-108 alone and in combination with anti-PD-1 as a potential treatment option for patients with advanced solid tumors. The implementation of the IO-108 program in China is part of the Company’s strategic plan to develop IO-108 globally. ...
All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and progression-free after at least one year. ...
” The European patent (EP3552617), titled “Drug Resistant Immunotherapy for Treatment of a Cancer”, provides additional coverage for the DRI-based approach to cell engineering. ...
Given IN8bio’s leadership role in the field of gamma-delta T cells, I am confident there are opportunities to form strategic relationships to accelerate the development of treatment for advanced cancers.” William Ho, Chief Executive Officer and co-founder of IN8bio, said, “IN8bio is a leader in gamma-delta T cell therapies with a deep pipeline of assets that ...
Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development, including IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for ...
Immune-Onc’s focused platform approach has led to the development of several promising therapeutics across various stages of development, including IO-108, an antagonist antibody targeting LILRB2 (also known as ILT4), in Phase 1 clinical development for solid tumors and IO-202, a first-in-class antagonist antibody targeting LILRB4 (also known as ILT3), in Phase 1 clinical development for ...
This research has rapidly advanced a completely new field of study and class of cancer immunotherapy that goes beyond T cells to overcome immune resistance and the limitations of current treatment options. We look forward to sharing our pipeline progress on the same stage with our Scientific Founder Dr. ...
IO-202 has two ongoing clinical studies: Its first Phase 1 trial is currently enrolling patients with acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML) as a monotherapy and in combination with azacitidine (NCT04372433). ...
Preclinical data demonstrate the use of gene circuits to improve the therapeutic potential of allogeneic CAR-NK cells for the treatment of solid tumors CAR-NK cells armed with calibrated release IL-15 achieve optimal cytokine distribution and result in superior killing and persistence Senti Bio, a leading gene circuit company, today announced new data from preclinical ...
Qualigen Therapeutics, Inc. is a diversified life sciences company focused on developing treatments for cancer, as well as maintaining and expanding its core FDA-cleared FastPack® System, which has been used successfully in diagnostics for over 20 years. ...
Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational natural killer (NK) cell therapy, CYNK-101, for treatment of gastric/gastroesophageal junction cancer. CYNK-101 is being developed as a first-line treatment in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients with locally advanced ...
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing treatments for cancer, as well as maintaining and expanding its core FDA-cleared FastPack® System, which has been used successfully in diagnostics for 20 years. ...
Qualigen is developing this platform’s lead compound, now called QN-302, as a potential treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. ...
Qualigen intends to develop the lead compound, now called QN-302, as a treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. ...